Author: Abdullah, Hadi Mohammed; Hama-Ali, Hersh H.; Ahmed, Sabah Nasraddin; Ali, Kosar Muhammad; Karadakhy, Kamaran Amin; Mahmood, Safeen Othman; Mahmood, Zana Hameed; Hamad Amin, Karmand Qadir; Atta, Peshnyar Muhammad; Nuradeen, Bryar Ezadeen; Mohammed, Shvan H.; Salih, Rawezh Q.; Baba, Hiwa O.; Kakamad, Fahmi H.
Title: A severe refractory COVID-19 patient responding to convalescent plasma; A case series Cord-id: 2r76ttp8 Document date: 2020_6_24
ID: 2r76ttp8
Snippet: INTRODUCTION: Although some medicines are under research, currently, no specific antiviral drug has been approved to target 2019 novel coronavirus. In this report two severe cases of 2019 novel coronavirus disease (COVID-19) patients have been described who received convalescent plasma (CP). CASE REPORT: Two male cases (a 46-year-old and a 56-year-old) after being diagnosed with severe COVID-19, they deteriorated despite supportive care and antiviral therapy. They started to improve with CP infu
Document: INTRODUCTION: Although some medicines are under research, currently, no specific antiviral drug has been approved to target 2019 novel coronavirus. In this report two severe cases of 2019 novel coronavirus disease (COVID-19) patients have been described who received convalescent plasma (CP). CASE REPORT: Two male cases (a 46-year-old and a 56-year-old) after being diagnosed with severe COVID-19, they deteriorated despite supportive care and antiviral therapy. They started to improve with CP infusion both clinically and radiologically. Finally they were discharged in a very well condition with negative virology tests. CONCLUSION: CP might be an effective therapy for severe COVID-19 patients.
Search related documents:
Co phrase search for related documents- abg arterial blood gas and lung injury: 1
- abg arterial blood gas and lymphocyte count: 1
- active antibody and lung injury: 1
- active formulation and lopinavir ritonavir: 1
- acute ards respiratory distress syndrome and liver function: 1, 2, 3, 4, 5, 6, 7, 8
- acute ards respiratory distress syndrome and liver function test: 1, 2
- acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and lopinavir ritonavir antiviral drug: 1
- acute ards respiratory distress syndrome and low grade fever: 1, 2, 3
- acute ards respiratory distress syndrome and lung infiltrate: 1
- acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- liver function and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- liver function and low grade fever: 1
- liver function and lung injury: 1
- liver function and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- liver function test and lopinavir ritonavir: 1, 2, 3
- liver function test and lymphocyte count: 1, 2, 3
- lopinavir ritonavir and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
Co phrase search for related documents, hyperlinks ordered by date